No connection

Search Results

CPHI vs LFWD

CPHI
China Pharma Holdings, Inc.
BEARISH
Price
$0.63
Market Cap
$25.5M
Sector
Healthcare
AI Confidence
95%
LFWD
Lifeward Ltd.
BEARISH
Price
$6.57
Market Cap
$24.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
CPHI
--
LFWD
--
Forward P/E
CPHI
--
LFWD
-5.21
P/B Ratio
CPHI
0.43
LFWD
1.19
P/S Ratio
CPHI
6.15
LFWD
1.13
EV/EBITDA
CPHI
-18.34
LFWD
-0.71

Profitability

Gross Margin
CPHI
-3.18%
LFWD
38.25%
Operating Margin
CPHI
-97.86%
LFWD
-112.69%
Profit Margin
CPHI
-76.92%
LFWD
-90.38%
ROE
CPHI
-20.91%
LFWD
-146.12%
ROA
CPHI
-8.41%
LFWD
-40.97%

Growth

Revenue Growth
CPHI
8.1%
LFWD
-32.7%
Earnings Growth
CPHI
--
LFWD
--

Financial Health

Debt/Equity
CPHI
0.17
LFWD
0.52
Current Ratio
CPHI
0.32
LFWD
1.31
Quick Ratio
CPHI
0.09
LFWD
0.69

Dividends

Dividend Yield
CPHI
--
LFWD
--
Payout Ratio
CPHI
0.0%
LFWD
0.0%

AI Verdict

CPHI BEARISH

CPHI exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity crisis. The company is operating with a negative gross margin (-3.18%), meaning it loses money on every product sold before operating expenses are even considered. With a current ratio of 0.32 and a quick ratio of 0.09, the firm lacks the liquid assets to cover its short-term obligations. This fundamental collapse is reflected in a catastrophic 5-year price decline of 99.8%.

Strengths
Low Debt/Equity ratio (0.17) suggests limited long-term leverage
Modest year-over-year revenue growth of 8.10%
Trading at a discount to book value (P/B 0.43)
Risks
Critical liquidity risk with a Current Ratio of 0.32
Negative gross margins indicate a non-viable core business model
Severe profitability collapse (Operating Margin -97.86%)
LFWD BEARISH

LFWD exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company is experiencing a collapse in top-line growth with revenue declining by 32.7% YoY, coupled with an unsustainable operating margin of -112.69%. Despite a low Price/Book ratio, the massive negative ROE (-146.12%) and consistent earnings misses (0/4 in the last year) suggest a failing business model. The extreme disconnect between the current price ($6.57) and the analyst target ($20.00) is not supported by any available fundamental data.

Strengths
Positive Gross Margin (38.25%)
Low Debt/Equity ratio (0.52) relative to sector average
Current Ratio above 1.0 (1.31)
Risks
Severe revenue contraction (-32.7% YoY)
Extreme profitability decay (Profit Margin -90.38%)
Critical Piotroski F-Score (1/9) signaling high risk

Compare Another Pair

CPHI vs LFWD: Head-to-Head Comparison

This page compares China Pharma Holdings, Inc. (CPHI) and Lifeward Ltd. (LFWD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile